GHRP-2 vs HGH
Well Studied vs FDA Approved
requires timing Mechanism-based · 51% GH secretagogues and exogenous GH compete via negative feedback. Exogenous GH suppresses natural GH pulses, reducing secretagogue efficacy. If combining, administer the secretagogue first and separate by 2+ hours.
Molecular Data
GHRP-2 HGH
Weight 817.9 Da 22,124 Da
Half-life ~30 minutes 3-4 hours (SC), 20-30 minutes (IV)
Chain 6 amino acids 191 amino acids
Type Synthetic hexapeptide Single-chain polypeptide with two disulfide bridges
Key Benefits
GHRP-2
01 Potent stimulation of natural growth hormone release
02 Enhanced muscle growth and recovery
03 Improved body composition and fat metabolism
04 Better sleep quality and recovery
05 Increased appetite (can be beneficial for bulking)
06 Maintains natural GH pulsatile release patterns
07 Synergistic effects when combined with GHRH peptides
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
GHRP-2
100-300 mcg / 2-3x daily
GH optimization 100-150 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Pre-sleep protocol 100-200 mcg Before bed
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
GHRP-2
Increased appetite (less than GHRP-6)
Mild water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetic retinopathy
WADA prohibited for competitive athletes
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
GHRP-2 HGH
Status Well Studied FDA Approved
References 3 studies 4 studies
Latest — 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.